Abingworth
Venture capital
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
8Deep-tech portfolio8 active
0Portfolio exitsAcquired or listed
3Raises, 12 monthsLatest: Iambic Therapeutics
9Co-investorsShare a portfolio company
Portfolio · 8 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Iambic Therapeutics | Biotech | Active | Sep 9, 2026 | $323.1M |
| Addition Therapeutics | Biotech | Active | Dec 22, 2025 | $28.0M |
| Solve Therapeutics | Biotech | Active | Nov 25, 2025 | $162.1M |
| Antares Therapeutics | Biotech | Active | May 15, 2025 | $70.0M |
| Glycomine | Biotech | Active | Nov 10, 2016 | $4.9M |
| AdvanCell | Biotech | Active | — | — |
| HotSpot Therapeutics | Biotech | Active | — | — |
| Myricx Bio | Biotech | Active | — | — |
Peer ranks
Portfolio size#53
Portfolio exits#234
Raises, 12 months#5
Co-investors#165
Co-investors
- Atlas VentureVenture capital2 shared
- Avalon VenturesVenture capital1 shared
- Bain Capital Life SciencesVenture capital1 shared
- Catalio Capital ManagementVenture capital1 shared
- MicrosoftVenture capital1 shared
- OrbiMedVenture capital1 shared
- Pfizer Venture InvestmentsVenture capital1 shared
- SR OneVenture capital1 shared
- SV Health InvestorsVenture capital1 shared
Sectors
- Biotech8
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.